1 / 16

Addressing the global HIV/AIDS epidemic: non-subtype B HIV-1 protease

Addressing the global HIV/AIDS epidemic: non-subtype B HIV-1 protease. C. Taylor Gilliland Mentor: Ben M. Dunn, Ph.D. Dept. of Biochemistry and Molecular Biology College of Medicine University of Florida. HIV/AIDS Epidemic Status. Source: 2006 Report on the Global AIDS Epidemic, UNAIDS, WHO.

lyndon
Download Presentation

Addressing the global HIV/AIDS epidemic: non-subtype B HIV-1 protease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Addressing the global HIV/AIDS epidemic: non-subtype B HIV-1 protease • C. Taylor Gilliland • Mentor: Ben M. Dunn, Ph.D. • Dept. of Biochemistry and Molecular Biology • College of Medicine • University of Florida

  2. HIV/AIDS Epidemic Status Source: 2006 Report on the Global AIDS Epidemic, UNAIDS, WHO

  3. HIV/AIDS Epidemic Status Source: 2006 Report on the Global AIDS Epidemic, UNAIDS, WHO

  4. HIV Genetic Epidemiology Takebe et al. (2004) Pediatrics International. 46. 236-244.

  5. Geographic Distribution of HIV-1 Subtypes and RFs F B B C D A,AG BF C Spira et al. (2003) J of Antimicrobial Chemotherapy. 51. 229-340.

  6. Role of HIV-1 Protease 1MUI 1MUI

  7. Non-Subtype B HIV-1 Proteases Studied in Dunn Lab

  8. Clinically Approved HIV-1 Protease Inhibitors

  9. Methodology

  10. Inhibitor RTV IDV SQV NFV APV LPV ATV TPV Subtype Ki (nM) B (LAI) 0.7 ± 0.1 1.8 ± 0.1 1.7 ± 0.4 2.2 ± 0.3 0.4 ± 0.1 0.11 ± 0.03 0.07 ± 0.01 0.4 ± 0.04 C 0.27 ± 0.06 3.3 ± 0.3 2.7 ± 0.3 2.6 ± 0.2 0.29 ± 0.03 0.2 ± 0.02 0.13 ± 0.01 0.13 ± 0.03 A 0.25 ± 0.03 2.1 ± 0.2 0.80 ± 0.06 2.0 ± 0.3 0.26 ± 0.03 0.03 ± 0.01 0.10 ± 0.02 0.56 ± 0.04 H 0.18 ± 0.03 1.7 ± 0.2 0.65 ± 0.10 1.5 ± 0.2 0.35 ± 0.07 1.1 ± 0.26 0.03 ± 0.004 0.22 ± 0.04 D 0.18 ± 0.03 2.1 ± 0.2 2.1 ± 0.2 3.1 ± 0.4 0.35 ± 0.06 0.07 ± 0.02 0.05 ± 0.01 0.43 ± 0.07 AC P81S 1.5 ± 0.2 10.2 ± 0.4 18.7 ± 0.7 5.1 ± 0.9 0.79 ± 0.09 2.3 ± 1.1 0.54 ± 0.06 0.9 ± 0.1 CRF-BF 0.07 ± 0.02 1.7 ± 0.2 0.74 ± 0.08 1.3 ± 0.2 0.46 ± 0.08 0.1± 0.2 0.06 ± 0.01 0.56 ± 0.05 F 0.77 ± 0.05 3.1 ± 0.5 1.3 ± 0.3 0.48 ± 0.02 0.41 ± 0.04 1.0 ± 0.16 0.81 ± 0.07 Inhibition of HIV-1 Pr

  11. Relative Fold Change in Ki Values of Non-Subtype B Pr Relative Fold Change Inhibitor

  12. Inhibitor RTV IDV SQV NFV APV LPV ATV TPV Subtype Ki (nM) URF-AC 0.48 ± 0.1 0.97 ± 0.1 1.2 ± 0.3 0.51 ± 0.2 0.089 ± 0.02 0.15 ± 0.02 0.1 ± 0.06 URF-AC P81S 1.46 ± 0.2 10.23 ± 0.37 18.7 ± 0.7 5.08 ± 0.89 0.79 ± 0.09 2.3 ± 1.1 0.54 ± 0.06 0.9 ± 0.1 B P81S 2.7 ± 0.2 0.81 ± 0.04 1.2 ± 0.2 0.52 ± 0.06 0.25 ± 0.03 Effect of P81S Mutation in URF-AC and Subtype B B PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF AC ------------V------R---------------IN---K---------------------------K-----------S-------M---------- Relative Fold Change Inhibitor

  13. Conclusions • - tight binding of inhibitors to all subtypes and recombinant forms • - effectiveness of tipranavir (TPV) • - P81S as possible secondary drug-resistance mutation • - continuing efforts to obtain first structure of non-subtype B HIV-1 protease

  14. Acknowledgments • Ben M. Dunn, Ph.D., College of Medicine, University of Florida • Roxana M. Coman, M.D., Dunn Lab • Melissa Marzahn, Dunn Lab • Marty Fernandez, Dunn Lab • Karan Desai, Dunn Lab • Alex Wlodawer, Ph.D., MCL, NCI-Frederick, NIH • Tinoush Moulaei, Ph.D., Wlodawer Lab • Arnold and Mabel Beckman Foundation

More Related